{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:30:09Z","timestamp":1784543409078,"version":"3.55.0"},"reference-count":36,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2010,7,14]],"date-time":"2010-07-14T00:00:00Z","timestamp":1279065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold><jats:styled-content>Purpose:<\/jats:styled-content>\u2002<\/jats:bold> To evaluate topiramate (TPM) and phenytoin (PHT) monotherapy following rapid oral initiation in new\u2010onset epilepsy.<\/jats:p><jats:p><jats:bold><jats:styled-content>Methods:<\/jats:styled-content>\u2002<\/jats:bold> Randomized, double\u2010blind, 28\u2010day trial of TPM (100\u2003mg\/day beginning on day 1) versus PHT (1,000\u2003mg on day 1 followed by 300\u2003mg\/day maintenance dosing) in 261 patients with new\u2010onset epilepsy. The primary end point was time to seizure, and the primary objective was to establish noninferiority of TPM to PHT in the risk of seizure.<\/jats:p><jats:p><jats:bold><jats:styled-content>Results:<\/jats:styled-content>\u2002<\/jats:bold> At day 28, the estimated seizure\u2010free rate was 81.1% for TPM treatment in comparison with 90.3% for PHT treatment. Noninferiority of TPM to PHT (primary objective) could not be established [hazard ratio (HR)\u20032.0, 95% confidence interval (CI), 0.98 to 4.12, p\u2003=\u20030.366), and PHT could not be shown to be superior to TPM. A higher percentage discontinued with PHT compared to TPM for all reasons (21.1 vs. 12.8%) and due to adverse events (13.4 vs. 6.8%). The most common treatment\u2010related adverse events in both groups were dizziness, paresthesia, and somnolence. A post hoc analysis showed that TPM was superior to PHT in time to discontinuation (retention rate) for all causes (89.4% vs. 80.3%, p\u2003=\u20030.047).<\/jats:p><jats:p><jats:bold><jats:styled-content>Conclusion:<\/jats:styled-content>\u2002<\/jats:bold> This study was inconclusive in establishing noninferiority of TPM 100\u2003mg\/day compared to a standard regimen of oral PHT in seizure risk in this population of patients with new\u2010onset epilepsy. Given the superiority of TPM in overall retention and favorable tolerability without titration, it may nonetheless be an appropriate option in some patients with new\u2010onset epilepsy requiring rapid treatment initiation.<\/jats:p>","DOI":"10.1111\/j.1528-1167.2010.02670.x","type":"journal-article","created":{"date-parts":[[2010,7,14]],"date-time":"2010-07-14T21:23:07Z","timestamp":1279142587000},"page":"1970-1977","source":"Crossref","is-referenced-by-count":31,"title":["Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new\u2010onset epilepsy: A randomized double\u2010blind clinical trial"],"prefix":"10.1111","volume":"51","author":[{"given":"Eugene","family":"Ramsay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Faught","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Krumholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Naritoku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Privitera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Schwarzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Wiegand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Hulihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the CAPSS\u2010272 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,7,14]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.305.6863.1215"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2005.00485.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200206000-00009"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01444.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(97)00024-7"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.10093"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2007.05.019"},{"key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1001\/jama.1980.03310130057036","article-title":"Status epilepticus. The role of intravenous phenytoin","volume":"244","author":"Cloyd JC","year":"1980","journal-title":"JAMA"},{"key":"e_1_2_8_10_1","unstructured":"DilantinPI. (2009)Parke\u2010Davis Division of Pfizer New York April 2009."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.6.743"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000048200.12663.BC"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073807303997"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00807.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199802123380704"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1553-2712.2001.tb00175.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000313151.64005.c0"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.2174\/138955708783331568"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60460-7"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60461-9"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198507183130303"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209103271104"},{"key":"e_1_2_8_23_1","unstructured":"Ortho\u2010McNeil(20032004).Ortho\u2010McNeil neurology consultant surveys 2003\u20132004."},{"key":"e_1_2_8_24_1","volume-title":"Topamax product information sheet","author":"Ortho\u2010McNeil","year":"2008"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(87)80360-8"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2003.00093.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2007.01.003"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00286.x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.9.1252"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1986.00520030053013"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06157.x"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb05562.x"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199008233230801"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-282X1999000500008"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1994.tb02931.x"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1973145797"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.18422"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2010.02670.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2010.02670.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T21:26:56Z","timestamp":1698787616000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2010.02670.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,14]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1528-1167.2010.02670.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2010.02670.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,14]]}}}